NCT06206135Recruiting
Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
Multicenter, Open, Prospective, 48 Weeks, Observational Study in the Real-world to Evaluate the Safety and Efficacy of Nephoxil Capsule for Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 172 (estimated)
- First submitted
- 17 Dec 2023
- Start date
- 21 Dec 2023
- Primary completion date
- 28 Feb 2028
- Lead sponsor
- LG Chem
- Diseases
- Chronic kidney disease
- NCT number
- NCT06206135
What you commit to
- Study type: Observational
- Planned participants: 172
- From 21 Dec 2023 to the primary completion date, 28 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those who require concomitant administration of aluminum-containing medication
Other
- Those who fall under the "Do not administer to the following patients" criteria according to Nephoxil capsule indication approval
- Others determined by the investigator to be unsuitable for participation in this study
Who the study is looking for
- Adults 19 years of age or older as of the ICF date
- CKD patients undergoing hemodialysis to whom Nephoxil capsule shall be administered for the first time for the treatment of hyperphosphatemia as per the determination of the investigator
- Patients who voluntarily decide to participate in this study and complete the ICF
Age in the registry: 19 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jesus Hospital Coordinator of this site? Confirm its status | Jeonju | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.